Company news
Glaukos Corporation (NYSE:GKOS) news
Glaukos Corporation news releases on 6ix. Latest, Jul 29, 2026: Glaukos Announces Second Quarter 2026 Financial Results
Press releases & updates
Glaukos Announces Second Quarter 2026 Financial Results
July 29, 2026
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
July 27, 2026
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
July 8, 2026
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
June 25, 2026
Glaukos Announces First Quarter 2026 Financial Results
April 29, 2026
Glaukos Announces the Release of its 2025 Sustainability Report
April 16, 2026
Glaukos Receives Permanent J-code for Epioxa™
April 15, 2026
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
April 8, 2026
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 6, 2026
Glaukos Announces Commercial Availability of Epioxa, a Transformative Innovation in Interventional Keratoconus Care
March 20, 2026
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
March 19, 2026
Glaukos : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K)
February 23, 2026
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
February 17, 2026
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose TR
January 29, 2026
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
January 28, 2026
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
January 20, 2026
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
January 13, 2026
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
December 16, 2025
Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel
December 4, 2025
Glaukos Announces Participation in Upcoming Investor Conferences
November 3, 2025
Glaukos Announces Third Quarter 2025 Financial Results
October 29, 2025
Glaukos Announces FDA Approval of Epioxa™
October 20, 2025
Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting
October 14, 2025
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29
October 8, 2025
Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama
September 25, 2025
Glaukos Announces Participation in Wells Fargo Healthcare Conference
August 13, 2025
Glaukos Announces Second Quarter 2025 Financial Results
July 30, 2025
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30
July 9, 2025
FELIQS Appoints Gregory Kunst and Joe Zenkus to Board of Directors
July 8, 2025
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies
June 25, 2025
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
June 25, 2025
Glaukos Announces First Quarter 2025 Financial Results
April 30, 2025
Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 23, 2025
Glaukos Announces the Release of its 2024 Sustainability Report
April 16, 2025
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30
April 9, 2025
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
February 24, 2025
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
February 20, 2025